U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015333) titled 'Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab' on May 25.
Brief Summary: Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.
Study Start Date: March 01, 2020
Study Type: OBSERVATIONAL
Condition:
Oral Squamous Cell Carcinoma (OSCC)
Intervention:
DRUG: pembrolizumab and cetuximab
Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab
Recruitment Status: COMPLETED
Sponsor: Commonwealth Healthcare Corporation
Information provided by (Responsible Party): Peter Brett, MD, Commonwealth Healthcare ...